<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> posts $15.4 million net loss for nine months ended September 2025
FibroBiologics Inc. reported a net loss of approximately $15.4 million for the nine months ended September 30, 2025, compared to a net loss of $8.1 million for the same period in 2024. General and administrative expenses were about $7.4 million for the first nine months of 2025, up from $6.9 million in 2024. The increase was mainly due to higher personnel costs, including stock-based compensation, increased professional fees, and travel expenses, partially offset by decreased expenses related to a Direct Listing. Cash and cash equivalents totaled approximately $4.9 million as of September 30, 2025. During the period, FibroBiologics advanced preparations to begin manufacturing its fibroblast-based spheroid product candidate, CYWC628, for a Phase 1/2 clinical trial in diabetic foot ulcer patients, scheduled for the first quarter of the following year. The company is also preparing to submit Investigational New Drug applications for CYPS317 for psoriasis and CYMS101 for multiple sclerosis, following the completion of pre-clinical IND-enabling studies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566385-en) on October 31, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.